Who Generates Higher Gross Profit? Vericel Corporation or Travere Therapeutics, Inc.

Vericel Surpasses Travere in 2023 Gross Profit

__timestamp	Travere Therapeutics, Inc.	Vericel Corporation
Wednesday, January 1, 2014	27632226	11503000
Thursday, January 1, 2015	97707000	24698000
Friday, January 1, 2016	129037000	26076000
Sunday, January 1, 2017	151332000	33570000
Monday, January 1, 2018	158719000	58697000
Tuesday, January 1, 2019	170104000	80279000
Wednesday, January 1, 2020	192195000	84228000
Friday, January 1, 2021	220706000	106025000
Saturday, January 1, 2022	204426000	109788000
Sunday, January 1, 2023	133788000	135576000

Unveiling the hidden dimensions of data

A Tale of Two Companies: Vericel Corporation vs. Travere Therapeutics, Inc.

In the competitive landscape of biotechnology, understanding which companies are leading in profitability can offer valuable insights. Over the past decade, Travere Therapeutics, Inc. and Vericel Corporation have been vying for dominance in gross profit generation. From 2014 to 2023, Travere Therapeutics consistently outperformed Vericel, with an average gross profit nearly double that of its competitor. However, the tide turned in 2023 when Vericel Corporation surpassed Travere, marking a significant shift in the industry. This change highlights Vericel's strategic advancements and market adaptability. As the biotech sector continues to evolve, these companies' financial trajectories offer a glimpse into the future of innovation and growth. Investors and industry watchers should keep a close eye on these trends as they unfold.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025